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Abstract
Background: Diagnosing centrally located lung tumors 
without endobronchial abnormalities and not located near 
the major airways is a diagnostic challenge. Tumors near or 
adjacent to the esophagus can be aspirated and detected 
with esophageal ultrasound (EUS) using gastrointestinal en-
doscopes. Objective: To assess the feasibility and diagnostic 
yield of endoscopic ultrasound with bronchoscope-guided 
fine needle aspiration (EUS-B-FNA) in paraesophageally lo-
cated lung tumors and its added value to bronchoscopy and 
endobronchial ultrasound (EBUS). Methods: Retrospective, 
multicenter international study (from January 1, 2015 until 
January 1, 2018) of patients with suspected lung cancer, un-
dergoing bronchoscopy, EBUS, and endoscopic ultrasound 
bronchoscopy (EUS-B) in one session by a single operator 
(pulmonologist), in whom the primary lung tumor was de-
tected and aspirated by EUS-B. In the absence of malignancy 
following endoscopy, transthoracic ultrasound needle aspi-
ration, clinical and radiological follow-up of at least 6 months 
was performed. The yield and sensitivity of EUS-B-FNA and 
its added value to bronchoscopy and EBUS was assessed. Re-
sults: 58 patients were identified with the following diagno-
sis: non-small-cell lung cancer (n = 43), small-cell lung cancer 
(n = 6), mesothelioma (n = 2), metastasis (n = 1), nonmalig-
nant (n = 6). The yield and sensitivity of EUS-B-FNA for de-
tecting lung cancer was 90%. In 26 patients (45%), the intra-
pulmonary tumor was exclusively detected by EUS-B. Add-
ing EUS-B to conventional bronchoscopy and EBUS increased 
the diagnostic yield for diagnosing lung cancer in para-
esophageally located lung tumors from 51 to 91%. No EUS-
B-related complications were observed. Conclusion: EUS-B-
FNA is a feasible and safe technique for diagnosing centrally 
located intrapulmonary tumors that are located near or ad-
jacent to the esophagus. EUS-B should be considered in the 
same endoscopy session following nondiagnostic bron-
choscopy and EBUS. © 2018 The Author(s)
Published by S. Karger AG, Basel
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Introduction
Lung cancer is the leading cause of cancer-related 
mortality worldwide [1]. In patients with suspected lung 
cancer, a tissue diagnosis is crucial to establish a definite 
diagnosis. However, for patients presenting with a cen-
trally located lung tumor without endobronchial abnor-
malities and not near the major airways, obtaining a tis-
sue diagnosis is a diagnostic challenge.
In routine practice, flexible bronchoscopy with its as-
sociated procedures (endobronchial biopsy, brushing, 
and washing) is performed, especially in case of a visible 
endobronchial tumor. However, frequently, no endo-
bronchial abnormalities are visible and in these situa-
tions, the diagnostic yield by standard bronchoscopic 
techniques is low [2–6]. Guidance techniques (radial en-
dobronchial ultrasound [EBUS]/fluoroscopy, naviga-
tion) can be helpful in peripherally located lung lesions in 
case an airway leads to the tumor but often do not con-
tribute to the diagnostic yield of these specific central le-
sions [7, 8].
If the tumor is located near or adjacent to the large air-
ways, endobronchial ultrasound transbronchial needle 
aspiration (EBUS-TBNA) is a useful and safe procedure 
to obtain a tissue diagnosis [9, 10]. 
With gastrointestinal endoscopes it has been proven 
that lung tumors located near or adjacent to the esoph-
agus can be detected and aspirated with esophageal ul-
trasound (EUS) [11]. However, this technique is not 
commonly available in most pulmonary practices. Cur-
rent lung cancer staging guidelines recommend endo-
scopic ultrasound bronchoscopy (EUS-B) (using the 
EBUS scope in the esophagus) for mediastinal staging, 
because this is complementary to EBUS for mediastinal 
nodal staging [12–15]. EBUS and EUS-B are also sug-
gested in this guideline for the analysis of lung tumors 
in patients with a centrally located lung tumor that are 
not visible with conventional bronchoscopy, provided 
that the tumor is located immediately adjacent to the 
larger airways (EBUS-TBNA) or esophagus (EUS-B/
EUS) [16].
To date, however, there is only limited evidence of the 
value of endoscopic ultrasound with bronchoscope-guid-
ed fine needle aspiration (EUS-B-FNA) for obtaining a 
tissue diagnosis in centrally located lung tumors [17, 18]. 
Therefore, we conducted this study to assess the feasibil-
ity and diagnostic yield of EUS-B in paraesophageally lo-
cated lung tumors and its added value to bronchoscopy 
and EBUS.
Methods
Study Design and Patients
This is a retrospective multicenter international study under-
taken in the Naestved Hospital, Naestved, Denmark (Department 
of Internal Medicine), the Zealand University Hospital, Roskilde, 
Denmark (Department of Internal Medicine), and in the Academ-
ic Medical Center (Department of Respiratory Medicine, Univer-
sity of Amsterdam), Amsterdam, the Netherlands, during the pe-
riod of January 1, 2015 until January 1, 2018. Patient data were 
retrieved for the various endosonography databases in the 3 hos-
pitals based on the following criteria: patients who underwent an 
EUS-B-FNA to obtain a tissue diagnosis of an intrapulmonary le-
sion for suspected lung cancer and also routinely underwent bron-
choscopy and EBUS.
Patient Selection
All patients in whom the paraesophageally located lung tumor 
was detected by EUS-B and sampled were identified. The present-
ed case is an example of the patient selection (Fig. 1). All CT and 
PET-CT imaging, bronchoscopy, EBUS, EUS-B reports, cytopa-
thological reports and follow-up data were collected. Also, compli-
cations of EUS-B were retrieved.
Study Endpoints
The primary endpoints of this study were to assess the diagnos-
tic yield of EUS-B and its added value to conventional bronchos-
copy and EBUS for obtaining a tissue diagnosis of centrally located 
lung tumors located near or adjacent to the esophagus. 
The secondary endpoints were the adequacy of the tissue sam-
ples and sensitivity of EUS-B for the diagnosis of a centrally lo-
cated lung tumor, the feasibility of EUS-B, and EUS-B-related 
complication for diagnosing an intrapulmonary tumor.
Definitions of Sample Adequacy, Yield, and Sensitivity
Biopsies were judged to be adequate when containing material 
sufficient for cytopathological evaluation. Samples in which cyto-
pathological evaluation showed malignancy were considered to be 
true positive.
When cytopathological evaluation of EUS-B-FNA samples 
showed no malignancy, the EUS-B diagnosis of the lung lesion was 
confirmed with at least 6 months of follow-up with clinical course 
and/or CT. For the calculation of the yield and sensitivity of ma-
lignancy, samples with a nonmalignant diagnosis without follow-
up were assumed to be false negative in the analyses (worst case 
scenario).
The diagnostic yield was defined as the number of samples in 
which EUS-B-FNA provided a correct diagnosis relative to the to-
tal number of samples assessed with EUS-B-FNA [11].
Sensitivity of malignancy was defined as the number of samples 
in which EUS-B-FNA diagnosed any malignancy relative to the 
total number of samples where the targeted intrapulmonary tumor 
turned out to be malignant [11].
The EUS-B Procedure
Procedures were performed under conscious sedation using 
midazolam/fentanyl or propofol sedation. Following a conven-
tional bronchoscopy, systematic EBUS was performed according 
to EBUS-STAT [19].
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Following EBUS, the EUS-B procedure will be discussed in 
more detail: for EUS-B-FNA, a flexible EBUS endoscope (Olym-
pus BF-UC180F or UC 180F, Olympus Medical Systems Europe, 
Ltd., Hamburg, Germany, or Pentax EB-1970 UK, Olympus BF-
UC180F) was used. 
The EBUS endoscope was introduced into the esophagus by 
retracting the EBUS scope from the trachea to a level just above the 
vocal cords and from this position turning it slightly to the left and 
the back of the patient and advancing it into the esophagus under 
gentle pressure while the patient was encouraged to swallow (in 
case of mild sedation). The endoscope was advanced carefully till 
the liver was visualized on ultrasound imaging.
A structured EUS assessment was performed using the 
esophageal assessment tool (EUS-AT) with 6 landmarks identi-
fied in this order: the liver, the abdominal aorta, the left adrenal 
gland, lymph node station 7, station 4L and 4R. This validated 
and systematic assessment tool is specifically developed for the 
examination of lung cancer patients [20]. Following the identi-
fication of the intrapulmonary tumor, aspirates were performed 
using a 21-G or a 22-G needle (22 Gauge Olympus ViziShot and 
ViziShot 2, Olympus Medical Systems Europe, Ltd., Hamburg, 
Germany, or a 21- to 22-G COOK needle). When the needle was 
placed in the lesion under ultrasonic guidance, the stylet was re-
moved, and suction was applied, or the stylet was removed using 
the slow pull technique. At least two samples were taken. The 
aspirates were processed for both cytological smears and cell-
block analysis. A chest-X-ray was not performed routinely after 
the procedure.
Statistics
Data were nonparametric and presented with median and 
range. Data were processed using SPSS (IBM SPSS Statistics, ver-
sion 22. Chicago, IL, USA).
Ethics 
This retrospective analysis was conducted in accordance with 
the amended Declaration of Helsinki and publication of the data 
was approved by the Data Protection Agency in Denmark and the 
medical ethics committee in the Netherlands.
Results
Fifty-eight patients were identified who underwent 
EUS-B-FNA for diagnosing an intrapulmonary tumor 
between January 1, 2015 and January 1, 2018. Patient 
characteristics are shown in Table 1. Of the 58 patients, 
34 were female (59%) with a median age of 78 years. The 
aspirated lesions were localized in all lobes, with a median 
size of 55 mm. No EUS-B-related complications were ob-
served.
Final diagnoses were: non-small cell lung cancer (n = 
43; adenocarcinoma n = 26; squamous cell carcinoma n = 
12; non-small cell lung cancer not otherwise specified n = 
5), small cell lung cancer (n = 6), malignant mesothelioma 
a b
c
Fig. 1. A 68-year-old male, with a centrally 
located left upper lobe tumor located near the 
esophagus. a PET-CT scan shows FDG up-
take in the tumor but not in the hilar and me-
diastinal lymph nodes. b At conventional 
bronchoscopy, there were no endobronchial 
abnormalities and the tumor was not visible 
with EBUS. c With EUS-B – with the EBUS 
scope positioned in the flexible esophagus – 
an inhomogeneous solid-appearing lesion 
with a close relation to the pulmonary artery 
was detected. Fine needle aspiration showed 
an adenocarcinoma of the lung.
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(n = 2), and metastasis from extrapulmonary cancer (n = 
1, anal squamous cell carcinoma). In 6 patients, the diag-
nosis was nonmalignant (unspecific lesion; n = 1, infec-
tious cause n = 5; Table 1).
Fifty-three patients (91%) had a bronchoscopy and 
EBUS-TBNA was performed in the same session as EUS-
B. Five patients did not undergo bronchoscopy or EBUS 
due to respiratory problems (n = 2) or the endobronchial 
procedure was expected to be of little consequence in ob-
taining a tissue diagnosis (n = 3) due to the anatomical 
position of the lung lesion.
At bronchoscopy, in 14 patients (24%), the tumor was 
visualized and biopsied. All these samples showed a ma-
lignancy. The diagnostic yield of the bronchoscopy was 
26%. Another 14 patients (22%) underwent an EBUS. 
Thirteen of the samples obtained with EBUS were ade-
quate for cytopathological evaluation; in 11 cases, the 
samples showed malignancy, in 2 patients the aspirates 
were nonmalignant (1 showed a necrotizing granuloma-
tous inflammation consistent with tuberculosis and 1 
showed a reactive and inflammatory changes at cytopa-
thology with a clinical picture of pneumonia and full re-
gression on antibiotic treatment). The diagnostic yield of 
EBUS alone was 25%. Adding EBUS to the bronchoscopy 
raised the diagnostic yield from 26 to 51%. In 1 (2%) case, 
the tumor could be visualized but not biopsied with 
EBUS-TBNA.
All 58 patients underwent EUS-B; of these, 52 were di-
agnostic and 47 were diagnosed to be malignant. In 26 
patients (45%), the tumor was exclusively visualized and 
biopsied with EUS-B-FNA. The diagnostic yield for EUS-
B alone was 90%. Combining bronchoscopy, EBUS, and 
EUS-B resulted in a diagnostic yield of 91% (Fig. 2).
Of all the 58 samples included in the analysis, 55 (95%) 
samples were adequate. Of these, 85% (n = 47) were ma-
lignant and 15% (n = 8) were nonmalignant. Of these, 4 
cases had a clinical and radiological follow-up for at least 
6 months, the causes were infectious, and 1 case had the 
results confirmed in repeated EUS-B-FNA and follow-up 
CT (2 samples with reactive and inflammatory changes at 
cytopathology with confirmed microbiologic agents or 
full regression on antibiotic treatment, 2 samples showed 
necrotizing granulomatous inflammation consistent with 
tuberculosis and one sample showed inflammatory cells 
confirmed at re-examination). These 5 cases are consid-
ered true negative. In the 3 other cases, follow-up was not 
clinically relevant as the patients had the procedure per-
formed on suspicion of relapse of lung cancer, and relapse 
in mediastinal or neck lymph nodes was found. These 
cases were considered false negative.
Table 1. Baseline characteristics of the patients included in the analysis and final diagnosis after complete workup
Patients, n 58
Median age, years 78 (41–90)
Gender
Male
Female
24 (41)
34 (59)
Localization of the lung tumor
LUL
LLL
RUL
RML
RLL
20 (34)
6 (10)
18 (31)
1 (2)
13 (22)
Median tumor size long axis, mm 55 (7–120)
Final diagnosis after complete workup NSCLC, n = 43
(adenocarcinoma n = 26, squamous cell carcinoma n = 12, NSCLC-NOS n = 5)
SCLC, n = 6
Malignant mesothelioma, n = 2
Metastasis from an extrapulmonary tumor, n = 1
Nonmalignant, n = 6
(unspecific lesion n = 1, infection n = 5)
EUS-B-related complications none
Figures in parentheses are percentages or ranges. LUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe; RML, right middle 
lobe; RLL, right lower lobe; NSCLC, non-small-cell lung cancer; NOS, not otherwise specified; SCLC, small-cell lung cancer.
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Of the 3 (5%) inadequate samples, 2 cases had diagnos-
tic adequate samples performed with bronchoscopy or 
ultrasound-guided transthoracic needle aspiration in the 
same session as the EUS-B that showed malignancy. One 
lesion was followed with CT and showed regression of the 
lesion in 6 months. All 3 cases were considered false neg-
ative. Thus, a total of 52 lesions were considered as ma-
lignant.
Transthoracic needle aspiration biopsy was performed 
and was ultrasound guided in the same session as endo-
scopic procedures in 4 (7%) cases to obtain the final diag-
nosis; in 1 of these, the diagnosis was only established 
with transthoracic needle aspiration biopsy.
The sensitivity of EUS-B for diagnosing any malignan-
cy was 90% in this very selected population. 
Discussion
In this study, we evaluated the largest series (n = 58) of 
patients who underwent an EUS-B-FNA for diagnosing a 
centrally located lung tumor adjacent to the esophagus. 
We found that EUS-B is safe and has a high diagnostic 
yield and sensitivity (90%) for diagnosing malignancy. 
Adding EUS-B to a previous nondiagnostic bronchosco-
py and EBUS raised the diagnostic yield from 51 to 91%. 
Only one report described EUS-B for diagnosing cen-
trally located lung tumors. Steinfort et al. [17] showed in 
a small selected cohort study that in 26 out of 27 patients 
EUS-B was diagnostic. In this study, 10 lesions were inac-
cessible for bronchoscopic sampling and 9 lesions were 
inaccessible for EBUS-TBNA. Diagnoses were obtained 
in predominantly upper lobes and 1 pneumothorax oc-
curred. The current study shows that lung tumors located 
{
Patients with a supected para-esophageal located lung tumor
n = 58
Diagnostic samples
N
Diagnosis 
(tumor/other)
Diagnostic 
bronchoscopy 
n = 14
(n = 14/n = 0)
Diagnostic EBUS 
n = 13
(n = 11/n =2)
Diagnostic EUS-B 
n = 52
(n = 47/n =5)
Diagnosis 
(n = 52/n =6)
Bronchoscopy
26 % (14/53)
EBUS 25 % (13/53)
Bronchoscopy 
+ EBUS
51% (27/53)
EUS-B alone
90% (52/58)
Broncho + EBUS 
+ EUS-B
91% (53/58) 
Flexible bronchoscopy
n = 53a
EBUS
n = 53a
EUS-B 
n = 58
Diagnosis by
bronchoscopy/EBUS/
EUS-B n = 53
Transthoracic needle
aspiration n = 1
Clinical and radiological
follow up n = 4d 
Diagnostic yieldb
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Fig. 2. Flowchart of patients with a central-
ly located lung tumor who underwent, in a 
single session, bronchoscopy, EBUS and 
EUS-B to obtain a diagnosis of the tumor.
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in all different lobes can be visualized and biopsied safely 
with EUS-B. 
In a systematic review and meta-analysis for diagnos-
ing intrapulmonary lung tumors by EUS using the gastro-
intestinal endoscope, Korevaar et al. [11] showed an aver-
age yield of 0.90 and an average sensitivity of 0.92. The 
complication rate was low with 2%. Our findings show 
similar results, indicating that tumor sampling by EUS-B 
lead to similar results as the conventional EUS scope. The 
potential advantages of the gastrointestinal EUS scope are 
the following: the larger overview (120–180° depended on 
the scope manufacturer vs. 60° visualization of EBUS), the 
needle length (10 vs. 6 cm), the slightly superior ultra-
sound quality (due to the increased amount of ultrasound 
crystals of the EUS transducer), and the increased stiffness 
of the scope. However, in clinical practice, all of the above-
mentioned items were rated not significant and not a lim-
iting factor for the diagnostic yield of the EUS-B approach.
An advantage of using EUS-B instead of convention 
gastrointestinal EUS scope for diagnosing lung tumors is 
that the whole diagnostic and staging procedure can be 
performed in a single endoscopy session performed by 
one operator. In our study, 91% of the patients also un-
derwent a conventional bronchoscopy and EBUS in the 
same session and mediastinal staging was performed in 
this single session. However, in 45% of the patients, the 
lung tumor was only detected and biopsied by EUS-B 
showing the benefit of this transesophageal approach.
An additional advantage of EUS-(B) is that it can be 
helpful in assessing mediastinal tumor invasion (T4). We 
have shown that in patients with paraesophageally locat-
ed lung tumor the EUS assessment (presents absences of 
mediastinal tumor invasion) has added important value 
to the CT scan of the chest [21].
Although CT-guided transthoracic needle aspirations 
for centrally located parabronchial lesions can be techni-
cally undertaken, the significant drawbacks are a high risk 
of pneumothorax and hemoptysis [16]. In addition, the 
diagnostic yield is lower than for peripheral lesions [10, 
22, 23].
It should be noted that several limitations apply to 
this study. First the retrospective character of this study 
means that there is a large bias of patient selection and 
the data should be interpreted accordingly. Second, this 
study analyzed data from 3 centers with expert EUS-B 
operators. It remains unclear if less experienced endos-
copists can achieve similar results. Third visualization 
of intrapulmonary tumors from the esophagus is only 
possible if the tumor is located near or adjacent to the 
esophagus. The maximum distance from the tumor to 
the esophagus is unknown. In the present study, virtu-
ally all tumors were located adjacent to the esophagus. 
Whether a specific air space between the wall of the 
esophagus and the lung tumor (as seen on the CT) still 
allows lung tumor detection by EUS-B needs to be in-
vestigated. As the esophagus is located in the left poste-
rior chest, this most often applies to central located left-
sided tumors. 
Future studies should include larger cohorts in a pro-
spective consecutive design. Our results provide further 
support that pulmonologists staging lung cancer should 
be trained in EUS-B-FNA [10]. 
Conclusion
EUS-B-FNA is a feasible and safe technique for diag-
nosing centrally located intrapulmonary tumors that are 
located near or adjacent to the esophagus. EUS-B should 
be considered in the same endoscopy session following a 
nondiagnostic bronchoscopy and EBUS.
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